Literature DB >> 12015758

A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus.

Yoshiaki Ogawa1, Masao Tanaka, Ken Inoue, Koji Yamaguchi, Kazuo Chijiiwa, Kazuhiro Mizumoto, Nobutaka Tsutsu, Yoshihiro Nakamura.   

Abstract

BACKGROUND: The correlation between diabetes mellitus and pancreatic carcinoma is well documented, but no criteria have been established for the efficient selection of a high-risk group among patients with diabetes mellitus.
METHODS: Eighty-seven patients were selected prospectively from outpatients with diabetes and underwent endoscopic retrograde pancreatography (ERP) according to the authors' original criteria, including the onset of diabetes after age 55 years, deterioration of diabetes or loss of body weight despite strict medical control, elevation of serum amylase and/or CA19-9 levels, and pancreatobiliary abnormalities on routine ultrasonography. The patients were divided into two groups according to the time from the onset of diabetes to ERP: Patients in Group A had recent-onset diabetes (within 3 years), and Group B patients had diabetes for > 3 years.
RESULTS: A total of 86 patients (excluding 1 patient with unsuccessful ERP who had undergone previous Billroth-2 gastrectomy) were enrolled. There were 33 males and 53 females, age 40-90 years, with a mean age of 65.1 years. ERP demonstrated pancreatic carcinoma, although it was advanced disease in all patients, at an extremely high rate of 7.0% (6 of 86 patients) with no serious complications. The prevalence of pancreatic carcinoma in Group A (13.9%; 5 of 36 patients) was significantly greater compared with Group B (2.0%; 1 of 50 patients; P = 0.0442). ERP with an indwelling balloon catheter and subsequent pancreatic juice sampling was performed in 49 patients, yielding positive cytology in 1 patient with pancreatic tail carcinoma, whereas measurements of carcinoembryonic antigen and CA19-9 levels in pancreatic juice were of no use in the diagnosis of pancreatic carcinoma.
CONCLUSIONS: Selective ERP in patients with diabetes who were at high risk did not lead to the early diagnosis of pancreatic carcinoma, although this study showed that the 3-year period after the onset of diabetes was critical. A more aggressive diagnostic approach within this period in diabetic patients with the authors' criteria may contribute to the earlier diagnosis of pancreatic carcinoma. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10493

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12015758     DOI: 10.1002/cncr.10493

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  34 in total

Review 1.  Detecting early pancreatic cancer: problems and prospects.

Authors:  Suresh T Chari
Journal:  Semin Oncol       Date:  2007-08       Impact factor: 4.929

2.  Antidiabetic Medications and Mortality Risk in Individuals With Pancreatic Cancer-Related Diabetes and Postpancreatitis Diabetes: A Nationwide Cohort Study.

Authors:  Jaelim Cho; Robert Scragg; Stephen J Pandol; Mark O Goodarzi; Maxim S Petrov
Journal:  Diabetes Care       Date:  2019-06-21       Impact factor: 19.112

3.  Tumour markers in internal medicine: a low-cost test or an unnecessary expense? A retrospective study based on appropriateness.

Authors:  D Arioli; M Pipino; E Boldrini; E Amateis; A Cristani; P Ventura; E Romagnoli; M C De Santis; M L Zeneroli
Journal:  Intern Emerg Med       Date:  2007-07-09       Impact factor: 3.397

4.  Does diabetes mellitus affect presentation, stage and survival in operable pancreatic cancer?

Authors:  Clement L K Chia; Anthea Y S Lee; Vishal G Shelat; Saleem Ahmed; Sameer P Junnarkar; Winston W L Woon; Jee-Keem Low
Journal:  Hepatobiliary Surg Nutr       Date:  2016-02       Impact factor: 7.293

Review 5.  Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.

Authors:  Phil A Hart; Melena D Bellin; Dana K Andersen; David Bradley; Zobeida Cruz-Monserrate; Christopher E Forsmark; Mark O Goodarzi; Aida Habtezion; Murray Korc; Yogish C Kudva; Stephen J Pandol; Dhiraj Yadav; Suresh T Chari
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-10-12

Review 6.  New insights into pancreatic cancer-induced paraneoplastic diabetes.

Authors:  Raghuwansh P Sah; Sajan Jiv Singh Nagpal; Debabrata Mukhopadhyay; Suresh T Chari
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-26       Impact factor: 46.802

7.  Probability of pancreatic cancer following diabetes: a population-based study.

Authors:  Suresh T Chari; Cynthia L Leibson; Kari G Rabe; Jeanine Ransom; Mariza de Andrade; Gloria M Petersen
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

Review 8.  Diabetes mellitus: a risk factor for pancreatic cancer?

Authors:  M Yalniz; P M Pour
Journal:  Langenbecks Arch Surg       Date:  2004-04-09       Impact factor: 3.445

9.  Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer.

Authors:  Rahul Pannala; Cynthia L Leibson; Kari G Rabe; Lawrence J Timmons; Jeanine Ransom; Mariza de Andrade; Gloria M Petersen; Suresh T Chari
Journal:  Am J Gastroenterol       Date:  2009-06-09       Impact factor: 10.864

Review 10.  Diagnosis and management of pancreatic cancer.

Authors:  A Collins; M Bloomston
Journal:  Minerva Gastroenterol Dietol       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.